Trexquant Investment LP decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 65.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,500 shares of the medical instruments supplier’s stock after selling 8,447 shares during the period. Trexquant Investment LP’s holdings in West Pharmaceutical Services were worth $425,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of WST. Russell Investments Group Ltd. purchased a new position in West Pharmaceutical Services during the fourth quarter worth $308,000. Teachers Advisors LLC increased its position in West Pharmaceutical Services by 8.1% in the fourth quarter. Teachers Advisors LLC now owns 65,966 shares of the medical instruments supplier’s stock worth $5,596,000 after buying an additional 4,954 shares during the period. Capstone Asset Management Co. increased its position in West Pharmaceutical Services by 2.4% in the first quarter. Capstone Asset Management Co. now owns 10,160 shares of the medical instruments supplier’s stock worth $829,000 after buying an additional 234 shares during the period. Louisiana State Employees Retirement System increased its position in West Pharmaceutical Services by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the medical instruments supplier’s stock worth $1,510,000 after buying an additional 400 shares during the period. Finally, Conestoga Capital Advisors LLC purchased a new position in West Pharmaceutical Services during the first quarter worth $908,000. 90.51% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services, Inc. (NYSE:WST) opened at 85.10 on Tuesday. The stock has a 50 day moving average price of $91.62 and a 200 day moving average price of $88.87. West Pharmaceutical Services, Inc. has a 12-month low of $70.17 and a 12-month high of $99.91. The company has a market capitalization of $6.30 billion, a price-to-earnings ratio of 36.52 and a beta of 1.10.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The company had revenue of $397.60 million during the quarter, compared to analyst estimates of $406 million. During the same period in the previous year, the business earned $0.59 EPS. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, analysts expect that West Pharmaceutical Services, Inc. will post $2.69 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be given a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a yield of 0.66%. The ex-dividend date of this dividend is Tuesday, October 17th. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. West Pharmaceutical Services’s payout ratio is 22.22%.

TRADEMARK VIOLATION WARNING: This story was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/west-pharmaceutical-services-inc-wst-position-lowered-by-trexquant-investment-lp/1489277.html.

A number of research analysts recently weighed in on WST shares. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Saturday, April 22nd. Jefferies Group LLC reaffirmed a “hold” rating and set a $90.00 price target (up from $82.00) on shares of West Pharmaceutical Services in a research note on Friday, April 28th. Finally, BidaskClub downgraded West Pharmaceutical Services from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. West Pharmaceutical Services currently has a consensus rating of “Hold” and a consensus price target of $90.18.

In other West Pharmaceutical Services news, CFO William J. Federici sold 54,996 shares of West Pharmaceutical Services stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $95.45, for a total value of $5,249,368.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.